Clinical advances on chimeric antigen receptor T cell therapy for glioblastoma

Jun CAO, Ye CHENG, Te⁃er BA, Feng LING, Qing⁃tang LIN

Abstract


Chimeric antigen receptor T cell (CAR⁃T) is a kind of genetically engineered T cells that can express tumor⁃associated antigen (TAA) specific receptors on its surface. The modified T cells can be used for cancer therapy by targeting its specific receptor and killing tumor cells with its cytotoxicity. CAR⁃T has been successfully applied to treat many kind of hematological malignancies. Recent clinical studies have reported CAR⁃T cell therapy to glioblastoma. However, it can affect the enrichment and function of T cells in glioblastoma. In this review, we discuss the mechanism, research status, challenges and prospects of CAR⁃T cell immunotherapy for glioblastoma.DOI：10.3969/j.issn.1672⁃6731.2020.02.006

Keywords


Glioblastoma; T-lymphocytes; Immunotherapy; Review

Full Text: PDF

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.